In COVID-19 patients, suppression of interferon (IFN) response has emerged as a major clinical determinant, with a complete loss of response associated with the most severe cases; a key differentiator from severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [58,59,60]. Here, IFNA1 is linked to Middle East respiratory syndrome.